Calidi Biotherapeutics Inc
CLDI
View Detailed Chart
0.239USD
-0.043-15.11%
Close 03/30, 16:00（ET）Quotes delayed by 15 min
1.08MMarket Cap
0.74P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-15.11%
5 Days
-15.65%
1 Month
-69.48%
6 Months
-84.50%
Year to Date
-79.60%
1 Year
-96.94%
View Detailed Chart
TradingKey Stock Score of Calidi Biotherapeutics Inc
Currency: USD Updated: 2026-03-27Key Insights
Calidi Biotherapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 163 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 10.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Calidi Biotherapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Calidi Biotherapeutics Inc Highlights
StrengthsRisks
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
Overvalued
The company’s latest PE is 0.83, at a high 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 34.73K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.93.
Analyst Rating
Based on
1
analysts
Strong Buy
Current Rating
10.000
Target Price
+4247.83%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Calidi Biotherapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Calidi Biotherapeutics Inc Info
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
Ticker SymbolCLDI
CompanyCalidi Biotherapeutics Inc
CEOPoma (Eric)
Websitehttps://www.calidibio.com/
Related Instruments
-1.16%
-0.37%
+1.36%
+5.68%
-0.69%
+0.95%
+0.45%
-1.22%
-0.40%
+0.67%
-2.98%
+0.25%
+0.57%
+0.60%
-2.33%
0.00%
-0.94%
-0.66%
-0.24%
+1.11%Popular Symbols
246.650
-6.240 (-2.47%)
165.060
-2.460 (-1.47%)
66450.010
-171.390 (-0.26%)
251.665
-21.685 (-7.93%)
2016.300
-4.400 (-0.22%)
355.270
-16.840 (-4.53%)
4499.120
-11.660 (-0.26%)
104.951
+0.689 (+0.66%)
1.145
-0.001 (-0.08%)
159.835
+0.176 (+0.11%)
